|Bid||0.1950 x 0|
|Ask||0.2600 x 0|
|Day's Range||0.0000 - 0.0000|
|52 Week Range|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||Oct 30, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Rapid Dose Therapeutics Corp. (CSE: DOSE) (“RDT” or the “Corporation”) in response to the COVID pandemic, recently made a donation to the Burlington Foodbank contributing over 16,000 QuickStrip™ Vitamin B12 product to distribute to those in need in the community, to support overall general health in these unprecedented times. RDT’s proprietary QuickStrip™ technology is a Quick, Convenient, Precise, Discreet™ oral, fast-dissolving drug delivery system that offers consumers an “anytime, anywhere” solution. To further our commitment to our customers, RDT is continuing to operate while carefully considering the safety of our employees and customers.
Rapid Dose Therapeutics Corp. (CSE: DOSE) (“RDT” or the “Corporation”) is pleased to announce that RDT has completed its first shipment of QuickStrip™ nutraceutical products to Peter Pan Brands. The QuickStrip™ nutraceutical product line will be distributed by Peter Pan Brands and sold across Ontario in multiple retail locations. RDT’s proprietary QuickStrip™ technology is a Quick, Convenient, Precise, Discreet™ oral, fast-dissolving drug delivery system that offers consumers an “anytime, anywhere” solution.
Rapid Dose Therapeutics Corp. (CSE: DOSE) (“RDT” or the “Corporation”) today announced that it has entered into an agreement for a drawdown equity financing facility (the “Investment Agreement”) with a single institutional investor. Subject to its terms and conditions and at the Company’s option, the Investment Agreement would provide RDT with up to C$10.0 million over a 24-month period to finance product development, continued expansion of distribution agreements and manufacturing capacity into global markets. The Investment Agreement is structured to provide RDT with relatively quick access to private placement financing, as and when, required.
Rapid Dose Therapeutics Corp. (CSE: DOSE) (“RDT” or the “Corporation”) is pleased to announce an Agreement with Perennial Brands, a DCM company, for the distribution and sale of nutraceutical oral dissolvable strip products in Canada, the United States and India for a period of three years. RDT will benefit from Perennial’s established global expertise in branding, marketing and distribution of consumer packaged goods (CPG) in the North American markets, combined with its strategic relationships in the fast-growing Indian market, and the backing of DCM, a North American leader in marketing services. “RDT is excited to continue to offer QuickStrip™ nutraceutical product formulations that are Quick, Convenient, Precise, and Discreet™ to Canadian, US and Indian audiences,” said Mark Upsdell, CEO, Rapid Dose Therapeutics.
Rapid Dose Therapeutics Corp. (CSE: DOSE) (“RDT” or the “Corporation”) is pleased to announce receipt of its Canada Revenue Agency (CRA) Cannabis Licence in February 2020, and now has obtained all approvals for cannabis processing and packaging for Canada. The licensing was required by RDT in order for RDT as a service provider to accept delivery of cannabis oil from its customers for RDT to process its customers’ cannabis oil into QuickStrip™ products at its Burlington, Ontario facility.
The funding will help RDT augment product development as well as enhance its manufacturing competency while creating new jobs and training skilled technical employees. “This grant funding award from NRC-IRAP will help support speed to market for RDT’s QuickStrip™ products and enable scale production capacity to supply global markets, demonstrate superior product performance for customers while strengthening the Company’s IP portfolio,” said Mark Upsdell, CEO and Founder of RDT.
This research program, which was successfully awarded a NSERC Collaborative Research and Development (CRD) grant, will receive a total funding amount of $540,000 over three years, effective January 1, 2020. The research collaboration will be led by the principal investigator, Dr. Alex Adronov and co-investigator Dr. Harald Stover, both of whom are full professors in the department of Chemistry and Chemical Biology at McMaster University.
Rapid Dose Therapeutics Corp. (CSE:DOSE) (“RDT” or the “Corporation”) is pleased to announce that all of the nominees listed in the Corporation’s management information circular dated November 11, 2019 were elected as directors of the Corporation at the Annual General and Special Meeting of Shareholders held today, Friday, December 6, 2019 (the “Meeting”) and all of the other matters considered by the shareholders at the Meeting were approved. Effective December 11, 2019, Miles Nagamatsu will be re-joining the Corporation as the interim Chief Financial Officer.
Rapid Dose Therapeutics Corp. (“RDT” or the “Corporation”) (CSE: DOSE) today reported that is has been issued a micro-processing licence by Health Canada for its Burlington, Ontario facility in accordance with the Cannabis Act and Cannabis Regulations. “This is a major milestone for RDT and will now enable us to produce QuickStrip™ cannabis products for both the Canadian medical and recreational markets,” said Mark Upsdell, CEO.
Rapid Dose Therapeutics Corp. (“RDT” or the “Corporation”) (CSE: DOSE) today reported its financial results for the second quarter of fiscal 2020, which ended on August 31, 2019. “We are very pleased to announce the recognition of revenue from the installation and commissioning of three QuickStrip™ production equipment systems,” said Mark Upsdell, CEO of RDT.
Rapid Dose Therapeutics Corp. (“RDT” or the “Corporation”) (CSE:DOSE) is pleased to announce that today it has completed the first closing of a private placement of common shares in the capital of the Corporation (“Common Shares”) at a price of $0.70 per Common Share for gross proceeds of $756,076 (the “Private Placement”). A total of 1,080,108 Common Shares were issued to investors, including a director and senior officer of RDT, in connection with the first closing of the Private Placement.
BURLINGTON, Ontario, Sept. 12, 2019 -- Rapid Dose Therapeutics Corp. (“RDT”) (CSE: DOSE) announced today that the results of a research study conducted by the University of.
BURLINGTON, Ontario, Sept. 10, 2019 -- Rapid Dose Therapeutics Corp. (“RDT”) (CSE: DOSE) announced today that the installation and commissioning of its QuickStrip™ production.
Chemesis International Inc. (CSE: CSI) (OTC: CADMF) (FRA: CWAA) (the “Company” or “Chemesis”), is proud to announce its subsidiary, Natural Ventures, has completed the installation, permitting, and testing phase of its QuickStrip™ oral thin strip production equipment. The Company has completed the previously announced commercialization strategy, and has begun accepting orders for QuickStrip for immediate distribution across Puerto Rico and the United States. Since receiving Gold Vendor Status from Rapid Dose Therapeutics Corp. (“RDT”) (CSE: DOSE) Chemesis has continued to work diligently to ensure the QuickStrip go to market strategy is done effectively and efficiently.
Rapid Dose Therapeutics Completes QuickStrip™ Equipment Installation in Puerto Rico and Grants Stock Options
BURLINGTON, ON, Aug. 20, 2019 /PRNewswire/ - Rapid Dose Therapeutics Corp. (CSE: DOSE), ("RDT") announced today the commencement of a clinical research trial with the GI Research Institute ("GIRI") and the University of British Columbia ("UBC") under the direction of Dr. Brian L. Bressler, MD, as Principal Investigator. The objective of this study is to evaluate the effectiveness of providing daily doses of QuickStrip™ Vitamin B12 oral thin film strips to Inflammatory Bowel Disease ("IBD") patients who are vitamin B12 deficient.
Rapid Dose Therapeutics and Thrive Cannabis Sign Manufacturing Agreement for QuickStrip™ Cannabis Products
BURLINGTON, ON , Aug. 1 , 2019 /CNW/ - Rapid Dose Therapeutics Corp. (CSE: DOSE), ("RDT") announced today that they have signed an amendment to the 12 month distribution agreement (the "Agreement") with Ukraine Pharma to expand the marketing and distribution of QuickStrip™ nutraceutical products to seven additional Eastern European countries with a combined population of over 240 million people. The additional countries are Armenia , Azerbaijan , Bangladesh , Jordan , Kazakhstan , Kyrgyzstan , and Uzbekistan , bringing distribution in Eastern Europe to a total of 11 countries. The Agreement now requires a minimum quarterly order of 1,890,000 of each of RDT's QuickStrip™ Energy, B12, and Sleep products. Ukraine Pharma has provided RDT with an updated and signed purchase order for a total of US$4.0 million and expects to expand its distribution by the beginning of 2020.
BURLINGTON, ON, July 30, 2019 /PRNewswire/ - Rapid Dose Therapeutics Corp. ("RDT") (CSE: DOSE) today reported its financial results for the first quarter of fiscal 2020, which ended on May 31, 2019. "This quarter represents a very exciting milestone for RDT as we commence the recognition of revenues from initial sales of our Energy, Vitamin B12, and Sleep QuickStrip™ nutraceutical products," said Mark Upsdell, CEO of RDT.
BURLINGTON, ON , July 25, 2019 /CNW/ - Rapid Dose Therapeutics Corp. ("RDT") (CSE: DOSE) announced today that they have completed the last phase of the Managed Strip Services Agreement (the "Agreement") signed in January 2019 with Flower One Holdings Inc. ("Flower One") (CSE: FONE) (OTCQX: FLOOF), pursuant to which Flower One has been granted Gold Vendor Status to manufacture, distribute and sell RDT's QuickStrip™, an innovative, proprietary delivery technology, for the cannabis market in Nevada, USA . Flower One is now initiating production of QuickStrip™ products for planned distribution later in 2019 to both the adult recreational and medical cannabis markets in Nevada , one of the most lucrative cannabis markets in the United States , hosting more than 55 million tourists annually from all over the globe.
BURLINGTON, ON , July 16, 2019 /CNW/ - Rapid Dose Therapeutics Corp. (CSE: DOSE), ("RDT") and Ukraine Pharma (the "Company") announced today that they have signed a twelve month distribution agreement (the "Agreement") to export QuickStrip™ nutraceutical products to Ukraine and a number of other Eastern European countries, giving the Company rights to market the Energy, B12, and Sleep QuickStrip™ nutraceutical products to a consumer base of over 200 million people with tremendous buying power.
BURLINGTON, ON and VANCOUVER , June 27, 2019 /CNW/ - Rapid Dose Therapeutics Corp. (CSE: DOSE), ("RDT") and Chemesis International Inc. (CSE: CSI) (OTC: CADMF) (FRA: CWAA) (the "Company") announced today that they have expanded the scope of their previously announced agreement (the "Agreement") expanding the territory where Chemesis has been granted Gold Vendor Status to license, manufacture, distribute and sell RDT's QuickStrip™ innovative, proprietary delivery technology for the medical cannabis market to Michigan, USA .